This company listing is no longer active
Provention Bio Past Earnings Performance
Past criteria checks 0/6
Provention Bio's earnings have been declining at an average annual rate of -36.7%, while the Pharmaceuticals industry saw earnings growing at 16.2% annually. Revenues have been growing at an average rate of 97.9% per year.
Key information
-36.7%
Earnings growth rate
-7.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 97.9% |
| Return on equity | -93.2% |
| Net Margin | -880.7% |
| Last Earnings Update | 31 Dec 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Provention Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 13 | -114 | 64 | 0 |
| 30 Sep 22 | 3 | -106 | 51 | 0 |
| 30 Jun 22 | 3 | -105 | 48 | 0 |
| 31 Mar 22 | 2 | -104 | 47 | 0 |
| 31 Dec 21 | 1 | -114 | 47 | 0 |
| 30 Sep 21 | 1 | -121 | 48 | 0 |
| 30 Jun 21 | 0 | -125 | 48 | -24 |
| 31 Mar 21 | 0 | -118 | 42 | -9 |
| 31 Dec 20 | 0 | -99 | 33 | 0 |
| 30 Sep 20 | 0 | -77 | 24 | 8 |
| 30 Jun 20 | 0 | -55 | 17 | 40 |
| 31 Mar 20 | 0 | -45 | 11 | 35 |
| 31 Dec 19 | 0 | -43 | 8 | 0 |
| 30 Sep 19 | 0 | -38 | 7 | 33 |
| 30 Jun 19 | 0 | -34 | 5 | 30 |
| 31 Mar 19 | 0 | -33 | 5 | 28 |
| 31 Dec 18 | 0 | -27 | 4 | 23 |
| 30 Sep 18 | 0 | -25 | 4 | 21 |
| 30 Jun 18 | 0 | -21 | 3 | 17 |
| 31 Mar 18 | 0 | -15 | 2 | 12 |
| 31 Dec 17 | 0 | -9 | 1 | 8 |
Quality Earnings: 2VB is currently unprofitable.
Growing Profit Margin: 2VB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2VB is unprofitable, and losses have increased over the past 5 years at a rate of 36.7% per year.
Accelerating Growth: Unable to compare 2VB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2VB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.9%).
Return on Equity
High ROE: 2VB has a negative Return on Equity (-93.2%), as it is currently unprofitable.